3R Pharma Overview
3R Pharma is developing high-end and complex cannabinoid-based pharmaceutical products to address chronic ocular diseases for patients around the world. These patent-pending cannabinoid-based medicines provide a novel treatment option for various conditions that are currently insufficiently addressed. The company's R&D unit, based in Israel, is licensed to conduct scientific and clinical research on cannabinoid formulations by the Ministry of Health IMC.
Cumulative Funding Raised Over Time ($)
—Feb 2023
$800KOct 2021
Latest News
growth-positive
3R Pharma Ltd. Announces the Appointment of Prof. Avi Solomon to its Scientific Advisory Board - 3R pharma
Prof. Avi Solomon has joined 3R Pharma Ltds Scientific Advisory Board to provide strategic guidance and clinical expertise for the companys research and development programs. 3R Pharma is a preclinical-stage pharmaceutical company focused on developing novel cannabinoid-based therapies for ophthalmic diseases. Prof. Solomon is an Associate Professor in the Ophthalmology Department at the Hadassah – Hebrew University Medical Center and specializes in ocular surface disorders and ocular surface diseases. His expertise will help 3R Pharma advance their pipeline of innovative therapies for serious ophthalmic conditions. The company is committed to bringing life-changing treatments to patients in need and improving their quality of life.
Partners
growth-positive
3R Pharma announces follow on investment from the "Israeli Innovation Authority" and "CanNegev" Incubator - 3R pharma
3R Pharma Ltd has received a follow-on investment from the Israeli Innovation Authority and CanNegev Start-Ups Incubator. The funding will be used to accelerate the companys drug development programs and advance its lead candidate into clinical trials. The investment is a testament to the progress made by 3R Pharma in advancing its drug development programs. Dry Eye and ocular surface diseases affect a significant portion of the population, and the global market for dry eye syndrome treatment and management is expected to reach USD 7.73 billion by 2027. 3R Pharmas lead candidate is a cannabinoid derived from cannabis plants that targets inflammatory pathways in the ocular surface of the eye. The company is focused on developing novel cannabinoid-based therapies for ophthalmic diseases.
Investment
growth-positive
3R Pharma announces seed investment - 3R pharma
3R Pharma, a biopharmaceutical company focused on ophthalmological conditions, has announced seed investment. The company has partnered with the CanNegev incubator, which is a joint venture between BOL Pharma, Perrigo, OurCrowd, and the Israeli Innovation Authority. The seed funding will be used to develop ophthalmic therapy based on active ingredients of the cannabis plant. 3R Pharma is located in Yeruham and will have access to office space and a fully equipped lab provided by the incubator. The founder and CEO, Michael Rubinov, expressed excitement about the investment and the companys product vision.
InvestmentPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $800K |
| Last funding | Undisclosed |
| Stage | Seed |
| Rounds | 2 |
| Investors | 5 |
Team Members
4
Employees: 1-10
Web & Social Links
| Website | www.3rpharma.com |
Locations
Yeruham, Israel
Photos & Videos
No files yet
3R Pharma Business
Business models
B2B
Product stage
R&D
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentMedical CannabisTarget Customer
Healthcare & Life SciencesHealthcareProvidersLife SciencesPharmaceuticalsCore Technology
BiologicalsHerbalsTags (9)
medical-cannabistherapeuticspharmaceuticalschronic-patientspatent-pendingcannabisophthalmologypatientstreatments3R Pharma Financials
$800K
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
Seed
Funding stage
2
Total rounds
5
Investors
Cumulative Funding Raised Over Time ($)
—Feb 2023
$800KOct 2021
Private Equity Funding
Seed
Feb 2023
Undisclosed
CanNegev
Pre-Seed
Oct 2021
$800K
Israel Innovation Authority, OurCrowd, Breath of Life Pharma, Padagis, CanNegev
3R Pharma Lifecycle
Cumulative Funding Raised Over Time
—Feb 2023
$800KOct 2021
All Events
Seed
Feb 2023
Undisclosed
CanNegev
Pre-Seed
Oct 2021
$800K
Israel Innovation Authority, OurCrowd, Breath of Life Pharma, Padagis, CanNegev
3R Pharma News
3 articles
growth-positive
3R Pharma Ltd. Announces the Appointment of Prof. Avi Solomon to its Scientific Advisory Board - 3R pharma
Prof. Avi Solomon has joined 3R Pharma Ltds Scientific Advisory Board to provide strategic guidance and clinical expertise for the companys research and development programs. 3R Pharma is a preclinical-stage pharmaceutical company focused on developing novel cannabinoid-based therapies for ophthalmic diseases. Prof. Solomon is an Associate Professor in the Ophthalmology Department at the Hadassah – Hebrew University Medical Center and specializes in ocular surface disorders and ocular surface diseases. His expertise will help 3R Pharma advance their pipeline of innovative therapies for serious ophthalmic conditions. The company is committed to bringing life-changing treatments to patients in need and improving their quality of life.
Partners
growth-positive
3R Pharma announces follow on investment from the "Israeli Innovation Authority" and "CanNegev" Incubator - 3R pharma
3R Pharma Ltd has received a follow-on investment from the Israeli Innovation Authority and CanNegev Start-Ups Incubator. The funding will be used to accelerate the companys drug development programs and advance its lead candidate into clinical trials. The investment is a testament to the progress made by 3R Pharma in advancing its drug development programs. Dry Eye and ocular surface diseases affect a significant portion of the population, and the global market for dry eye syndrome treatment and management is expected to reach USD 7.73 billion by 2027. 3R Pharmas lead candidate is a cannabinoid derived from cannabis plants that targets inflammatory pathways in the ocular surface of the eye. The company is focused on developing novel cannabinoid-based therapies for ophthalmic diseases.
Investment
growth-positive
3R Pharma announces seed investment - 3R pharma
3R Pharma, a biopharmaceutical company focused on ophthalmological conditions, has announced seed investment. The company has partnered with the CanNegev incubator, which is a joint venture between BOL Pharma, Perrigo, OurCrowd, and the Israeli Innovation Authority. The seed funding will be used to develop ophthalmic therapy based on active ingredients of the cannabis plant. 3R Pharma is located in Yeruham and will have access to office space and a fully equipped lab provided by the incubator. The founder and CEO, Michael Rubinov, expressed excitement about the investment and the companys product vision.
InvestmentPartners
3R Pharma Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 2 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
3R Pharma Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 97/100 |
| Missing | video or image, markets |
| BI Verification | Yotam Maman |
| Registrar ID | 516198264 |
| Phone | +972544742750 |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-07-03T00:00:00.000Z |
| Created | 2021-10-31T00:00:00.000Z |
| Claimed | Yes |